BCDA News and Press, BioCardia Inc. From 08/02/23

SUNNYVALE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and six months ended J...

2023-07-24 10:09:58 ET Gainers: Armata Pharmaceuticals ( ARMP ) +19% . Janux Therapeutics ( JANX ) +11% . Amylyx Pharmaceuticals ( AMLX ) +8% . Coherus BioSciences ( CHRS ) +7% . Nuwellis ( NUWE ) +7% . Losers: Kodiak...

SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its pre...

SUNNYVALE, Calif. , July 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it completed its submission of the CardiAMP Cell Therapy System to Japa...

2023-06-22 12:58:23 ET BioCardia ( NASDAQ: BCDA ) said on Thursday that on June 21, it entered into an agreement with certain directors and officers of the company. Under the agreement, BCDA agreed to sell and issue 1.1M shares of its common stock at an offering price of $2.33...

SUNNYVALE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that FDA Center for Biologics Evaluation and Research (CBER) has c...

SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Japan Patent Office has granted Patent No: JP7282649B2...

2023-05-30 08:50:56 ET Summary BioCardia has made significant progress in the development of its therapeutic candidates BCDA-01 and BCDA-02, which target ischemic heart failure and chronic myocardial ischemia, respectively. The company has received Breakthrough Device Designation ...

SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeting for the Card...

2023-05-10 20:25:04 ET BioCardia, Inc. (BCDA) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Miranda Peto – Investor Relations Peter Altman – President and Chief Executive Officer Dave McClung – Chief Financial ...